At a glance commentaryScientific background on the subjectThe Chang Gung Research Database (CGRD) is a database derived from original medical records of Chang Gung Memorial Hospital (CGMH). The volume of medical services in CGMH is large, and studies based on the CGRD are reported to be of high quality. However, the CGRD has not been analyzed before.What this study adds to the fieldThis study indicates the CGRD is a multi-institutional, original medical record-based research database with high overall and disease-specific coverage of Taiwan. The population of the CGRD has significantly higher severity of comorbidities, and prevalence of specific diseases than those of Taiwan NHIRD and medical centers in Taiwan.

The Chang Gung Research Database (CGRD) is a de-identified database derived from medical records of Chang Gung Memorial Hospital (CGMH), and it is systematically updated annually to include new data generated in CGMH. CGMH, founded in 1976, is currently the largest hospital system in Taiwan, and it comprises seven medical institutes, which are located from the northeast to southern regions of Taiwan: Keelung CGMH, Taipei CGMH, Linkou CGMH, Taoyuan CGMH, Yunlin CGMH, Chiayi CGMH, and Kaohsiung CGMH. CGMH has 10,070 beds and admits more than 280,000 patients each year. The outpatient department visits and emergency department visits to CGMH were over 8,500,000 and 500,000, respectively in 2015 [@bib1]. In recent years, the CGRD promoted clinical and scientific studies to a considerable extent. In 2015, more than 1800 studies were conducted by CGMH staff, and the studies were published in a diverse range of reputed journals. Some of these studies are based on the CGRD as multicenter research studies with relatively large sample sizes [@bib2], [@bib3].

Although the CGRD is a medical record database with large volumes of data that are useful to perform several research studies and analysis, its characteristics and coverage have never been reported before. The objective of this study was to analyze the CGRD with regard to its characteristics and coverage of Taiwan\'s population.

Methods {#sec1}
=======

Study population {#sec2.1}
----------------

We performed a nationwide cohort study using population-based data from the Taiwan National Health Insurance Research Database (NHIRD), one of the largest administrative health-care databases worldwide. The National Health Insurance (NHI) program, implemented on March 1, 1995, is a single-payer compulsory and universal health insurance plan, and it now covers all forms of health-care services for over 99% of Taiwan\'s residents [@bib4], [@bib5], [@bib6], [@bib7], [@bib8]. This high coverage rate (nearly 100%) enables studies based on the NHIRD to be nationwide and population-based. For researchers\' convenience, the National Health Research Institutes (NHRI) of Taiwan sampled a representative database of 1 million patients from the year 2000 registry of all NHI enrollees (*n* = 23,753,407) by using a systematic and random sampling method (Longitudinal Health Insurance Database, LHID2000) [@bib6]. In LHID2000, no statistically significant differences exist in age, sex, or health-care costs between the sample group and all enrollees, according to NHRI Reports [@bib6]. In this study, we used these databases for estimating outpatient visits and admissions of the sample cohort, as both include information about patient characteristics including sex, date of birth, date of admission, date of discharge, dates of outpatient visits, and up to three outpatient visit diagnoses and five discharge diagnoses \[based on the International Classification of Diseases, Ninth Revision (ICD-9) classification\] [@bib9]. These databases have previously been used for various scientific studies, and the information they provide about diagnoses, hospitalizations, and prescription use has been proved to be of high quality [@bib4], [@bib10], [@bib11], [@bib12]. The identification numbers of all patients in the NHIRD were encrypted to protect their privacy. The Ethics Review Board of our institution approved the study (CGMH-IRB No. 201600346B0).

Study design {#sec2.2}
------------

The flowchart of the patient enrollment process of study cohort is presented in [Fig. 1](#fig1){ref-type="fig"}. The study cohort was identified from LHID2000, which comprise 1 million beneficiaries. Complete data of all these beneficiaries were recorded from January 1, 1997, to December 31, 2010. We conducted a nationwide population-based cohort study that included all patients who had any medical record of outpatient visits or admission between January 1, 1997, and December 31, 2010 (*n* = 974,019). We excluded patients who died or dropped out from the NHI scheme before January 1, 2001, to allow for more than 4 years of study period. On the basis of this criterion, data on 44,587 patients were excluded. Finally, data on 929,432 patients were included in this study.Fig. 1Flowchart of the patient enrollment process of study cohort.Fig. 1

The claim data of each outpatient and inpatient visits sourced from the LHID2000 (a subset database of NHIRD) included the variables of "hospital grade" and "hospital ID". Patients with outpatient visits were categorized into three groups: Group 1, NHIRD (all patients); Group 2, Center \[patients with record of outpatient visit(s) in any medical center\]; Group 3, CGRD \[patients with record of outpatient visit(s) in CGMH\]. Accordingly, we also grouped patients with record of admission into Group 1 (NHIRD), Group 2 (Center), and Group 3 (CGRD).

Patients\' sociodemographic information including age, sex, socioeconomic status, and urbanicity level was obtained from enrollment data files in LHID2000. The sociodemographic information such as age, socioeconomic status, and urbanicity level might change over time. Thus, to define the patients\' sociodemographic information in the same period is necessary for fair comparison. In this study, we used a subset database of NHIRD -- LHID2000 which contained one million enrollnees. All the enrollnees in LHID2000 had initial registry data of NHIRD during 1996--2000 which was used to define their sociodemographic information. The enrollee category (EC) of all patients was registered in National Health Insurance Research Database (NHIRD). This study used EC as a measure of socioeconomic status to classify beneficiaries into four subgroups (EC 1--EC 4): EC 1 (civil servants, full-time, or regularly paid personnel in governmental agencies and public schools, and self-employed people); EC 2 (employees of privately owned enterprises or institutions); EC 3 (other employees or paid personnel, and members of the farmers\' or fishers\' associations); and EC 4 (substitute service draftees, members of low-income families, and veterans). On average, the payroll-related amount for health insurance was highest for EC 1, followed by EC 2, EC 3, and EC 4 [@bib13]. To determine the level of urbanicity among the study cohort, we classified all 359 townships in Taiwan into three categories: urban, suburban, and rural areas. The urbanicity classification was based on five indices: population density, percentages of residents with college or higher education, percentages of residents aged \>65 years, percentages of residents who were agriculture workers, and the number of physicians per 100,000 people [@bib14]. We used Deyo\'s Charlson Comorbidity Index (CCI) to evaluate the comorbidities of patients, and the CCI score was calculated from January 1, 1997, to December 31, 2010, using the ICD-9 coding system [@bib15]. The leading causes of death, most common catastrophic diseases and chronic diseases in Taiwan were also studied and defined as follows: cancer (ICD-9 codes as 140--208), liver cirrhosis (ICD-9 codes 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 572.8, and 573.0), stroke (ICD-9 codes 430--438), coronary artery disease (CAD; ICD-9 codes 410--414), chronic kidney disease (CKD; ICD-9 codes 582, 583, 585, 586, and 588), hypertension (ICD-9 codes 401--405), diabetes mellitus (DM; ICD-9 codes 250), hyperlipidemia (ICD-9 codes 272), chronic obstructive pulmonary disease (COPD; ICD-9 codes 491, 492, 496), asthma (ICD-9 codes 493), pneumonia (ICD-9 codes 480--486 and 507.0--507.8), hepatitis B (ICD-9 codes 070.2, 070.3, and V02.61), hepatitis C (ICD-9 codes 070.7, 070.41, 070.44, 070.51, 070.54, and V02.62), mental disease (ICD-9 codes 290--319) [@bib16], [@bib17].

Statistical analysis {#sec2.3}
--------------------

Basic demographic data were summarized as *n* (%) for categorical variables and mean with standard deviation for continuous variables. Distribution of comorbidities was tabulated as *n* (%). We used Chi-square test for comparison between three groups, and used Fisher\'s exact test for pairwise comparison between each group. SAS version 9.4 (SAS Inc., Cary, NC, USA) was used for statistical analysis.

Results {#sec3}
=======

Patient characteristics {#sec3.1}
-----------------------

A total of 929,432 patients were included as the study cohort; among the patients, 923,044 had outpatient visits (outpatient samples) and 376,448 had admission to a hospital (inpatient samples). The demographic characteristics of the patients are presented in [Table 1](#tbl1){ref-type="table"}. The sex ratio, age distribution, socioeconomic status, and urbanicity of the population of the CGRD are different from those of Taiwan NHIRD and medical centers in Taiwan for both outpatient and inpatient samples (all the pairwise *p* \< 0.05).Table 1Baseline characteristics for outpatient and inpatient in NHIRD, Center, and CGRD.Table 1OutpatientInpatientNHIRDCenterCGRDNHIRDCenterCGRD*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)Total923,044552,451195,529376,448164,94546,520Gender Male468,155 (50.7)264,304 (47.8)91,048 (46.6)180,732 (48.0)82,795 (50.2)23,092 (49.6) Female454,889 (49.3)288,147 (52.2)104,481 (53.4)195,716 (52.0)82,150 (49.8)23,428 (50.4)Age Mean (SD)29.3 (19.8)31.2 (19.9)31.9 (20.0)36.0 (21.1)39.0 (21.1)38.7 (21.0) 0--9183,622 (19.9)92,165 (16.7)32,293 (16.5)43,754 (11.6)16,963 (10.3)5219 (11.2) 10--19123,242 (13.4)75,376 (13.6)22,804 (11.7)42,053 (11.2)14,170 (8.6)3458 (7.4) 20--29179,398 (19.4)104,186 (18.9)36,879 (18.9)73,755 (19.6)26,531 (16.1)7257 (15.6) 30--39168,971 (18.3)98,695 (17.9)35,279 (18.0)60,079 (16.0)26,627 (16.1)7673 (16.5) 40--49118,407 (12.8)77,257 (14.0)28,730 (14.6)51,874 (13.8)25,770 (15.6)7398 (15.9) 50--5964,808 (7.0)45,407 (8.2)18,068 (9.2)38,510 (10.2)20,043 (12.2)6144 (13.2) 60--6956,588 (6.1)40,918 (7.4)15,543 (8.0)42,553 (11.3)23,052 (14.0)6494 (14.0) 70--7923,380 (2.5)16,056 (2.9)5276 (2.7)19,953 (5.3)10,203 (6.2)2508 (5.4) ≥804628 (0.5)2391 (0.4)657 (0.3)3917 (1.0)1586 (1.0)369 (0.8)EC 167,561 (7.3)46,060 (8.3)14,662 (7.5)25,458 (6.8)13,204 (8.0)2981 (6.4) 2433,418 (47.0)262,002 (47.4)92,847 (47.5)158,484 (42.1)69,626 (42.2)19,191 (41.3) 3287,917 (31.2)163,103 (29.5)63,446 (32.5)129,518 (34.4)53,829 (32.6)18,150 (39.0) 4134,148 (14.5)81,286 (14.7)24,574 (12.6)62,988 (16.7)28,286 (17.2)6198 (13.3)Urbanicity Urban282,100 (30.6)199,443 (36.1)64,091 (32.8)106,263 (28.2)57,842 (35.1)12,486 (26.8) Suburban436,915 (47.3)249,791 (45.2)94,549 (48.4)175,537 (46.6)73,789 (44.7)23,202 (49.9) Rural204,029 (22.1)103,217 (18.7)36,889 (18.9)94,648 (25.1)33,314 (20.2)10,832 (23.3)[^1][^2][^3][^4]

For the outpatient samples, the case numbers for Group 1, Group 2, and Group 3 were 923,044, 552,451, and 195,529, respectively. The sex ratio (i.e., male-to-female ratio) was 50.7/49.3 in Group 1, 47.8/52.2 in Group 2, and 46.6/53.4 in Group 3. Both Groups 2 and 3 showed 3--4% female predominance compared with Group 1. The mean age of patients in Groups 1, 2, and 3 was 29.3 ± 19.8, 31.2 ± 19.9, and 31.9 ± 20.0 years, respectively. The mean age and age distribution in Group 2 were close to those in Group 3; compared with Group 1, the other two groups had a slight increase in patients in the 40--69-year age group (approximately 2%) and a decline in those in the 0--9-year age group (approximately 3%). The urbanicity level in Group 1 was close to that in Group 3, and both groups had a reduction in urban population (3.3--5.5%), compared with Group 2.

Regarding the inpatient samples, the case numbers for Groups 1, 2, and 3 were 376,488, 164,945, and 46,520, respectively. The sex ratio (i.e., male-to-female ratio) was 48.0/52.0 in Group 1, 50.2/49.8 in Group 2, and 49.6/50.4 in Group 3. Group 1 showed 1--2% female predominance compared with Groups 2 and 3. The mean ages of patients in Groups 1, 2, and 3 were 36.0 ± 21.1, 39.0 ± 21.1, and 38.7 ± 21.0 years, respectively. The mean age and age distribution in Group 2 were close to those in Group 3; compared with Group 1, the other two groups had a slight increase in patients in the 40--69-year age group (nearly 2--3%) and a drop in those in the 10--29-year age group (approximately 3--4%). The urbanicity level in Group 1 was close to that in Group 3, and both groups had a slight increase in suburban and rural populations (2--5%) and a reduction in urban population (approximately 7--8%) compared with Group 2.

Severity and prevalence of comorbidities {#sec3.2}
----------------------------------------

The patient comorbidities are listed in [Table 2](#tbl2){ref-type="table"}. The severity of comorbidities, and prevalence of specific diseases of the population of the CGRD are significantly higher than those of Taiwan NHIRD and all medical centers in Taiwan for both outpatient and inpatient samples (all the pairwise *p* \< 0.05). Regarding the outpatient samples, Groups 3 was determined to be tended to have a higher CCI score and higher prevalence of specific comorbidities than did Group 1 and Group 2. In Group 3, the prevalence rates of cancer, hepatitis C, and liver cirrhosis were 1.6 times higher than those in Group 1. Other diseases also showed higher prevalence rates (CKD was 1.5 times higher; stroke, COPD, asthma, DM, hyperlipidemia, CAD, and mental disease were 1.4 times higher; and hepatitis B, hypertension, and pneumonia were 1.3 times higher) in Group 3, compared with Group 1.Table 2Comorbidities for outpatient and inpatient in NHIRD, Center, and CGRD.Table 2OutpatientInpatientNHIRDCenterCGRDNHIRDCenterCGRD*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)*n* (%)Total923,044552,451195,529376,448164,94546,520CCIs ≤4835,669 (90.5)482,396 (87.3)166,831 (85.3)299,804 (79.6)119,517 (72.5)32,824 (70.6) \>487,375 (9.5)70,055 (12.7)28,698 (14.7)76,644 (20.4)45,428 (27.5)13,696 (29.4)Disease Cancer49,537 (5.4)42,212 (7.6)17,043 (8.7)44,141 (11.7)30,248 (18.3)8855 (19.0) Liver cirrhosis15,351 (1.7)11,836 (2.1)5196 (2.7)13,753 (3.7)8162 (5.0)2874 (6.2) Hepatitis C12,630 (1.4)9622 (1.7)4242 (2.17)9660 (2.6)5135 (3.1)1829 (3.9) CKD38,264 (4.2)30,124 (5.5)12,559 (6.4)30,175 (8.0)17,585 (10.7)5354 (11.5) Stroke66,742 (7.2)50,266 (9.1)19,721 (10.1)55,976 (14.9)29,816 (18.1)8653 (18.6) COPD85,196 (9.2)63,019 (11.4)25,210 (12.9)59,705 (15.9)30,173 (18.3)8606 (18.5) Asthma85,704 (9.3)60,809 (11.0)25,584 (13.1)49,955 (13.3)22,814 (13.8)7039 (15.1) Diabetes mellitus100,013 (10.8)73,364 (13.3)28,681 (14.7)69,083 (18.4)36,389 (22.1)10,784 (23.2) Hyperlipidemia142,059 (15.4)105,737 (19.1)41,635 (21.3)81,850 (21.7)42,392 (25.7)12,130 (26.1) CAD94,152 (10.2)72,175 (13.1)27,353 (14.0)68,935 (18.3)36,864 (22.4)9677 (20.8) Mental disease220,716 (23.9)164,655 (29.8)65,045 (33.3)128,946 (34.3)61,536 (37.3)17,423 (37.5) Hepatitis B33,091 (3.6)24,987 (4.5)9236 (4.7)18,516 (4.9)9684 (5.9)2799 (6.0) Hypertension196,365 (21.3)139,939 (25.3)52,781 (27.0)126,519 (33.6)65,381 (39.6)18,547 (39.9) Pneumonia90,154 (9.8)63,868 (11.6)24,405 (12.5)70,359 (18.7)33,913 (20.6)9939 (21.4)[^5][^6][^7]

For the inpatient samples, Groups 3 was observed to be tended to have a higher CCI score and higher prevalence rates of specific comorbidities than did Group 1 and Group 2. In Group 3, the prevalence rates of liver cirrhosis, cancer, hepatitis C, and CKD were 1.7, 1.6, 1.5, and 1.4 times higher than those in Group 1. Other diseases also demonstrated higher prevalence rates (DM was 1.3 times higher; stroke, COPD, hyperlipidemia, hepatitis B, and hypertension were 1.2 times higher; and asthma, CAD, mental disease, and pneumonia were 1.1 times higher) in Group 3 compared with Group 1.

Population coverage {#sec3.3}
-------------------

The overall and disease-specific coverage rates of the CGRD and medical centers are illustrated in [Fig. 2](#fig2){ref-type="fig"}. For the outpatient samples, the overall coverage rate of the CGRD was 21.2% and the disease-specific coverage rate was 27--34%. The disease with the highest coverage rates were cancer (34%), liver cirrhosis (34%), hepatitis C (34%), and CKD (33%). Regarding the inpatient samples, the overall coverage rate of the CGRD was 12.4% and the disease-specific coverage rate was 14--21%. The disease with the highest coverage rates were liver cirrhosis (21%), cancer (20%), hepatitis C (19%), and CKD (18%).Fig. 2The coverage of the CGRD and medical centers for the outpatients (A) and inpatients (B) samples.Fig. 2

Discussion {#sec4}
==========

To the best of our knowledge, this is the first study to evaluate the characteristics and coverage of a database of a private hospital system. The study results reveal the sex ratio, age distribution, socioeconomic status, urbanicity, severity of comorbidities, and prevalence of diseases of the population of the CGRD are different from those of Taiwan NHIRD and medical centers in Taiwan. Population of CGRD is tended to have a higher CCI score and higher prevalence of specific comorbidities than those of NHIRD and medical centers in Taiwan. The findings reveal CGRD could be a suitable database for studying patients with more severe and complicated diseases. The overall coverage of the CGRD was 21.2% for outpatients and 12.4% for inpatients ([Fig. 2](#fig2){ref-type="fig"}). Among the total number of NHI enrollees in the year 2000 (*n* = 23,753,407), the CGRD included data on 5 million patients for the outpatient sample and 2.9 million patients for the inpatient sample. Cancer, liver cirrhosis, and hepatitis C had the highest outpatient coverage rate (34%), whereas their inpatient coverage rate was 20%. These proportions accounted for 8.1 million outpatient and 4.8 million inpatient samples in the CGRD. This large sample size of the CGRD, including data on cancer, catastrophic diseases, and chronic diseases facilitates a large number of studies in these areas.

Being a large database, our results supported the CGRD to be suitable for use in public health and epidemiologic studies. In addition, the CGRD enhances statistical power when studying rare diseases or infrequent outcomes. Because the CGRD is updated annually, researchers can perform longitudinal studies from 2000, the year from which electronic medical records of CGMH became available. Staff members of CGMH who fulfill the requirements of conducting research projects are eligible to apply for the CGRD. Because data in the CGRD are not collected for a specific study, the observer-expectancy effect is minimized and the objectiveness of collected data is strengthened. Being free of cost, the concern about grant support is less pressing. According to experience of conducting studies based on the Taiwan NHIRD and UK General Practice Research Database, the low cost required to access CGRD data can considerably promote scientific research. NHIRD studies have rapidly expanded in both quantity and quality since the first study was published in 2000 [@bib18]. Hence, the CGRD, which has numerous advantages, is expected to be a highly competitive database.

In contrast to the NHIRD, which contains secondary data from billing order and charge codes, the CGRD contains original data, and is therefore superior to the NHIRD. A critical limitation of the NHIRD is that it lacks data on examination results and health behavior; however, these are documented and comprehensively detailed in the CGRD. Second, the accuracy of diagnosis in the NHIRD is often criticized. By contrast in the CGRD, the diagnosis can be proved or supported by pathology studies and laboratory or other examinations. Third, the NHIRD does not include any data on self-pay or trial settings, which are accessible in the CGRD [@bib19]. These advantages render the CGRD superior to the NHIRD. Cancer studies on the basis of the NHIRD are often criticized because of the lack of stage and histological classifications, which could be studied more completely in CGRD-based studies [@bib20], [@bib21]. In hepatitis studies, more precise diagnosis of samples can be established (hepatitis B, hepatitis C, or alcoholic hepatitis with or without liver cirrhosis) according to the history, unhealthy habits, serologic test results, and abdominal sonography report available in the CGRD.

Some challenges exist for the CGRD. First, although the government center of CGMH is expanding considerable effort to protect patients\' privacy, it is necessary to keep pace with time and amount of data collected and stored and continue to protect patients\' privacy. Second, with the increasing utilization of the CGRD, more human resources with more specialized work will be required. Third, data collected before 2000 were traditional paper medical records and these are not currently available for researchers. Fourth, as long as the patients have ever visited other hospital for any medical issues, their medical information in CGRD won\'t be completed. Therefore, in the future, the CGRD should continue to improve with time and look forward to contribute more to human health studies worldwide.

Conclusions {#sec5}
===========

The CGRD is a multi-institutional, original medical record-based research database with high overall and disease-specific coverage of Taiwan. The population of the CGRD have significantly higher severity of comorbidities, and prevalence of specific diseases than those of Taiwan NHIRD and medical centers in Taiwan.

Conflicts of interest {#sec6}
=====================

The authors declare that they have no competing interest.

The study was financially supported by grants from the Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C. (CGRPG6G0011). The authors would like to thank Center of Excellence for Chang Gung Research Datalink (CORPG6D0161-2, CORPG6D0251-2) for the comments and assistance in data analysis.

Peer review under responsibility of Chang Gung University.

[^1]: Abbreviation: SD: standard deviation.

[^2]: Enrollee category (EC) as a proxy measure of socio-economic status (SES).

[^3]: Chi-square test for comparison between three groups. All the *p*-value were \<0.05.

[^4]: Fisher\'s exact test for pairwise comparison between each group. All the pairwise *p* \< 0.05.

[^5]: Abbreviations: CCI: Charlson Comorbidity Index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease.

[^6]: Chi-square test for comparison between three groups. All the *p*-value were \<0.05.

[^7]: Fisher\'s exact test for pairwise comparison between each group. All the pairwise *p* \< 0.05, except hypertension, hyperlipidemia, COPD, hepatitis B, Mental disease for the inpatient samples between Center and CGRD (*p* \> 0.05).
